Skip to main content
SpringerLink
Log in

Lipoproteins and the Development of Restenosis After Stent Implantation in the Superficial Femoral Artery in Patients with Peripheral Artery Disease

  • Clinical Investigation
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Purpose

High levels of apolipoprotein B (apo B) are a risk factor for the development of major vascular events. We evaluated the association between plasma lipoproteins and the development of superficial femoral artery (SFA) in-stent restenosis and reocclusion in patients with peripheral artery disease.

Materials and Methods

We included 139 patients with SFA stenting. Plasma lipoproteins were measured after stent implantation. Stent restenosis was assessed with duplex scan after 3, 6, and 12 months. A stenosis grade was considered relevant if >50%.

Results

Seventy-two patients experienced recurrence of their atherosclerotic disease, meaning restenosis of >50% within 1 year of follow-up. Ten of these patients had a stent occlusion. In the patients who experienced recurrence, the mean apo B level was 105.8 versus 94.9 mg/dl in patients without recurrence (P < 0.05). Patients without recurrence had higher high-density lipoprotein cholesterol levels than patients with recurrence (39.7 vs. 34.7 mg/dl, P < 0.05). Comparing patients with a stent occlusion (n = 10) and those with a restenosis of 75–99% (n = 28), the patients with a stent occlusion had higher levels of plasma cholesterol (234.1 vs. 185.9 mg/dl, P < 0.05), apo B (135.3 vs. 99.8 mg/dl, P < 0.05), low-density lipoprotein cholesterol (160.3 vs. 113.6 mg/dl, P < 0.05), and low-density lipoprotein apo B (115.5 vs. 82.4 mg/dl, P < 0.001) than the patients with restenosis of 75–99% (n = 28).

Conclusion

Changes in the lipid profile could be one reason for the development of restenosis and for the development of reocclusion after SFA stenting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sniderman AD, Furberg CD, Keech A et al (2003) Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361(9359):777–780

    Article  PubMed  CAS  Google Scholar 

  2. Graham I, Atar D, Borch-Johnsen K et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28:2375–2414

    Article  PubMed  Google Scholar 

  3. Walldius G, Aastveit AH, Jungner I (2006) Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 259:259–266

    Article  PubMed  CAS  Google Scholar 

  4. Walldius G, Jungner I, Holme I et al (2001) High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358(9298):2026–2033

    Article  PubMed  CAS  Google Scholar 

  5. Walldius G, Jungner I (2004) Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 255:188–205

    Article  PubMed  CAS  Google Scholar 

  6. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A (2007) Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 27:661–670

    Article  PubMed  CAS  Google Scholar 

  7. Maca T, Ahmadi R, Derfler K et al (2002) Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in type 2 diabetic patients. Diabet Med 19:300–306

    Article  PubMed  CAS  Google Scholar 

  8. Giovanetti F, Gargiulo M, Laghi L et al (2009) Lipoprotein(a) and other serum lipid subfractions influencing primary patency after infrainguinal percutaneous transluminal angioplasty. J Endovasc Ther 16:389–396

    Article  PubMed  Google Scholar 

  9. Diehm N, Shang A, Silvestro A et al (2006) Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg 31:59–63

    Article  PubMed  CAS  Google Scholar 

  10. Wanner C, Horl WH, Luley CH, Wieland H (1991) Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 39:754–760

    Article  PubMed  CAS  Google Scholar 

  11. Bachorik PS, Ross JW (1995) National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on lipoprotein measurement. Clin Chem 41:1414–1420

    PubMed  CAS  Google Scholar 

  12. Ruef J, Hofmann M, Haase J (2004) Endovascular interventions in iliac and infrainguinal occlusive artery disease. J Interv Cardiol 17:427–435

    Article  PubMed  Google Scholar 

  13. Isner JM, Rosenfield K (1993) Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization. Circulation 88(4 pt 1):1534–1557

    PubMed  CAS  Google Scholar 

  14. Klein AJ, James Chen S, Messenger JC et al (2009) Quantitative assessment of the conformational change in the femoropopliteal artery with leg movement. Catheter Cardiovasc Interv 74:787–798

    Article  PubMed  Google Scholar 

  15. Mwipatayi BP, Hockings A, Hofmann M et al (2008) Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: a meta-analysis. J Vasc Surg 47:461–469

    Article  PubMed  Google Scholar 

  16. Ferrieres J, Gousse ET, Fabry C, Hermans MP (2008) Assessment of lipid-lowering treatment in France—the CEPHEUS study. Arch Cardiovasc Dis 101:557–563

    Article  PubMed  Google Scholar 

  17. Goldbourt U, Yaari S, Medalie JH (1997) Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8,000 men. Arterioscler Thromb Vasc Biol 17:107–113

    Article  PubMed  CAS  Google Scholar 

  18. Nofer JR, Levkau B, Wolinska I et al (2001) Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276:34480–34485

    Article  PubMed  CAS  Google Scholar 

  19. Gordon DJ, Probstfield JL, Garrison RJ et al (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8–15

    Article  PubMed  CAS  Google Scholar 

  20. Barter P (2000) CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 20:2029–2031

    Article  PubMed  CAS  Google Scholar 

  21. Spieker LE, Sudano I, Hurlimann D et al (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105:1399–1402

    Article  PubMed  CAS  Google Scholar 

  22. Delgado-Lista J, Lopez-Miranda J, Cortes B et al (2008) Chronic dietary fat intake modifies the postprandial response of hemostatic markers to a single fatty test meal. Am J Clin Nutr 87:317–322

    PubMed  CAS  Google Scholar 

  23. Hoebe K, Georgel P, Rutschmann S et al (2005) CD36 is a sensor of diacylglycerides. Nature 433(7025):523–527

    Article  PubMed  CAS  Google Scholar 

  24. Valiyaveettil M, Kar N, Ashraf MZ et al (2008) Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 111:1962–1971

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Angiology, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria

    Thomas Gary, Peter Rief, Harald Froehlich, Franz Hafner, Ernst Pilger & Marianne Brodmann

  2. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria

    Tatjana Stojakovic & Hubert Scharnagl

Authors
  1. Thomas Gary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Rief
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatjana Stojakovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harald Froehlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hubert Scharnagl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Franz Hafner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ernst Pilger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marianne Brodmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Gary.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gary, T., Rief, P., Stojakovic, T. et al. Lipoproteins and the Development of Restenosis After Stent Implantation in the Superficial Femoral Artery in Patients with Peripheral Artery Disease. Cardiovasc Intervent Radiol 34, 739–743 (2011). https://doi.org/10.1007/s00270-010-0030-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-010-0030-9

Keywords

Search

Navigation